Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Edwards Lifesciences Corp., historical price multiples (quarterly data)
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Edwards Lifesciences Corp. P/E ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Edwards Lifesciences Corp. P/OP ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Edwards Lifesciences Corp. P/S ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Edwards Lifesciences Corp. P/BV ratio decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Price to Earnings (P/E)
Edwards Lifesciences Corp., historical P/E calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 623,207,437 | 624,334,496 | 623,327,843 | 621,636,777 | 624,518,873 | 623,248,273 | 621,740,581 | 619,664,253 | 627,367,734 | 625,710,042 | 623,907,657 | 625,504,809 | 623,298,987 | 627,147,807 | 628,157,934 | 632,337,345 | 630,071,124 | 634,859,673 | 633,474,090 | 629,408,397 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||
| Net income (loss) (in thousands) | 335,300 | 340,100 | 489,500 | 338,200 | 309,500 | 325,200 | (121,900) | 310,600 | 280,200 | 274,700 | 242,300 | 249,700 | 7,000 | 225,900 | 282,700 | 206,600 | (2,800) | 170,100 | 186,100 | 230,200 | ||||||
| Earnings per share (EPS)2 | 2.41 | 2.37 | 2.35 | 1.37 | 1.32 | 1.27 | 1.20 | 1.79 | 1.67 | 1.24 | 1.16 | 1.22 | 1.16 | 1.14 | 1.05 | 0.89 | 0.93 | 0.00 | 0.00 | 0.00 | ||||||
| Share price1, 3 | 107.73 | 119.82 | 112.27 | 96.78 | 87.65 | 78.08 | 78.69 | 71.05 | 76.85 | 76.07 | 70.95 | 58.71 | 59.26 | 46.71 | 47.29 | 43.10 | 44.61 | 33.97 | 38.50 | 36.56 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||||
| P/E ratio4 | 44.67 | 50.64 | 47.85 | 70.70 | 66.48 | 61.28 | 65.79 | 39.74 | 46.05 | 61.52 | 61.07 | 47.99 | 51.14 | 41.12 | 45.24 | 48.67 | 48.16 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||||
| Abbott Laboratories | 29.13 | 31.42 | 33.80 | 36.79 | 48.49 | 58.45 | 58.36 | 45.61 | 41.83 | 44.92 | 53.17 | 52.98 | 56.47 | 136.66 | 122.73 | 213.07 | 220.29 | — | — | — | ||||||
| Bristol-Myers Squibb Co. | 20.92 | — | — | — | — | — | — | 144.77 | 41.99 | 16.53 | 11.97 | 14.51 | 16.81 | 56.09 | 251.38 | 92.56 | 103.55 | — | — | — | ||||||
| CVS Health Corp. | 17.39 | 16.78 | 14.94 | 14.44 | 12.88 | 10.69 | 10.20 | 10.94 | 14.15 | 20.65 | 17.46 | — | — | 25.50 | 23.08 | 10.05 | 10.69 | — | — | — | ||||||
| Danaher Corp. | 29.94 | 38.81 | 37.87 | 39.26 | 44.49 | 46.61 | 41.91 | 35.88 | 38.34 | 40.31 | 41.93 | 37.63 | 29.77 | 25.70 | 27.06 | 27.78 | 27.25 | — | — | — | ||||||
| Elevance Health Inc. | 18.13 | 18.65 | 22.10 | 19.99 | 15.87 | 14.35 | 11.97 | 14.80 | 15.96 | 15.55 | 18.14 | 16.19 | 21.45 | 15.64 | 14.84 | 14.70 | 15.44 | — | — | — | ||||||
| Intuitive Surgical Inc. | 59.94 | 71.86 | 69.15 | 89.95 | 87.47 | 82.17 | 70.73 | 44.27 | 48.72 | 49.80 | 51.02 | 53.16 | 53.03 | 73.32 | 73.33 | 69.50 | 70.95 | — | — | — | ||||||
| Medtronic PLC | 46.56 | 55.13 | 42.80 | 32.34 | 26.30 | 25.38 | 31.86 | 32.75 | 28.78 | 25.11 | 57.38 | 41.16 | 37.80 | 37.82 | 21.55 | 26.35 | 29.96 | — | — | — | ||||||
| UnitedHealth Group Inc. | 26.03 | 27.92 | 27.41 | 23.06 | 20.54 | 17.70 | 16.88 | 19.91 | 20.48 | 17.79 | 17.98 | 17.93 | 21.09 | 21.18 | 20.91 | 20.02 | 20.77 | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2021 Calculation
EPS
= (Net income (loss)Q4 2021
+ Net income (loss)Q3 2021
+ Net income (loss)Q2 2021
+ Net income (loss)Q1 2021)
÷ No. shares of common stock outstanding
= (335,300,000 + 340,100,000 + 489,500,000 + 338,200,000)
÷ 623,207,437 = 2.41
3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.
4 Q4 2021 Calculation
P/E ratio = Share price ÷ EPS
= 107.73 ÷ 2.41 = 44.67
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Edwards Lifesciences Corp. P/E ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021. |
Price to Operating Profit (P/OP)
Edwards Lifesciences Corp., historical P/OP calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 623,207,437 | 624,334,496 | 623,327,843 | 621,636,777 | 624,518,873 | 623,248,273 | 621,740,581 | 619,664,253 | 627,367,734 | 625,710,042 | 623,907,657 | 625,504,809 | 623,298,987 | 627,147,807 | 628,157,934 | 632,337,345 | 630,071,124 | 634,859,673 | 633,474,090 | 629,408,397 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||
| Operating income (loss) (in thousands) | 374,400 | 390,300 | 542,100 | 383,500 | 351,400 | 357,800 | (169,700) | 358,100 | 310,800 | 294,300 | 267,500 | 274,200 | (5,300) | 248,900 | 252,100 | 252,500 | 342,200 | 214,000 | 241,000 | 298,300 | ||||||
| Operating profit per share2 | 2.71 | 2.67 | 2.62 | 1.48 | 1.44 | 1.38 | 1.28 | 1.99 | 1.83 | 1.33 | 1.26 | 1.23 | 1.20 | 1.75 | 1.69 | 1.66 | 1.74 | 0.00 | 0.00 | 0.00 | ||||||
| Share price1, 3 | 107.73 | 119.82 | 112.27 | 96.78 | 87.65 | 78.08 | 78.69 | 71.05 | 76.85 | 76.07 | 70.95 | 58.71 | 59.26 | 46.71 | 47.29 | 43.10 | 44.61 | 33.97 | 38.50 | 36.56 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||||
| P/OP ratio4 | 39.72 | 44.87 | 42.81 | 65.18 | 60.98 | 56.78 | 61.66 | 35.77 | 42.04 | 57.30 | 56.37 | 47.70 | 49.37 | 26.74 | 28.00 | 25.96 | 25.66 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||
| Abbott Laboratories | 24.45 | 26.84 | 29.01 | 31.39 | 40.69 | 45.82 | 45.19 | 35.87 | 34.03 | 34.32 | 37.50 | 36.74 | 36.64 | 38.12 | 38.00 | 39.99 | 60.88 | — | — | — | ||||||
| Bristol-Myers Squibb Co. | 19.84 | — | — | — | — | 39.45 | 33.97 | 27.33 | 24.42 | 13.51 | 10.89 | 13.68 | 16.16 | 19.56 | 27.48 | 23.10 | 28.87 | — | — | — | ||||||
| CVS Health Corp. | 10.43 | 9.43 | 7.87 | 7.61 | 6.65 | 5.89 | 5.98 | 6.19 | 7.83 | 9.44 | 8.02 | 15.80 | 18.65 | 12.59 | 11.14 | 6.90 | 7.44 | — | — | — | ||||||
| Danaher Corp. | 25.14 | 32.12 | 30.83 | 32.62 | 36.91 | 46.28 | 43.09 | 35.22 | 34.47 | 29.97 | 30.85 | 26.85 | 23.18 | 20.95 | 21.72 | 22.58 | 22.48 | — | — | — | ||||||
| Elevance Health Inc. | 15.70 | 15.81 | 19.93 | 15.79 | 12.10 | 10.93 | 9.03 | 11.95 | 13.55 | 12.60 | 14.74 | 12.58 | 15.87 | 15.01 | 14.22 | 14.34 | 14.81 | — | — | — | ||||||
| Intuitive Surgical Inc. | 56.11 | 67.95 | 69.51 | 89.18 | 88.37 | 83.88 | 71.30 | 43.68 | 48.89 | 50.00 | 49.12 | 51.89 | 49.87 | 48.90 | 50.69 | 46.82 | 44.40 | — | — | — | ||||||
| Medtronic PLC | 37.44 | 49.88 | 42.55 | 35.86 | 26.29 | 21.01 | 23.52 | 22.21 | 21.26 | 19.74 | 21.13 | 20.04 | 17.64 | 16.73 | 17.82 | 19.53 | 22.64 | — | — | — | ||||||
| UnitedHealth Group Inc. | 18.77 | 19.63 | 19.05 | 16.12 | 14.12 | 12.35 | 11.85 | 13.80 | 14.40 | 12.43 | 12.51 | 12.48 | 14.58 | 15.82 | 15.19 | 14.17 | 14.42 | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2021 Calculation
Operating profit per share
= (Operating income (loss)Q4 2021
+ Operating income (loss)Q3 2021
+ Operating income (loss)Q2 2021
+ Operating income (loss)Q1 2021)
÷ No. shares of common stock outstanding
= (374,400,000 + 390,300,000 + 542,100,000 + 383,500,000)
÷ 623,207,437 = 2.71
3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.
4 Q4 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 107.73 ÷ 2.71 = 39.72
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Edwards Lifesciences Corp. P/OP ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021. |
Price to Sales (P/S)
Edwards Lifesciences Corp., historical P/S calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 623,207,437 | 624,334,496 | 623,327,843 | 621,636,777 | 624,518,873 | 623,248,273 | 621,740,581 | 619,664,253 | 627,367,734 | 625,710,042 | 623,907,657 | 625,504,809 | 623,298,987 | 627,147,807 | 628,157,934 | 632,337,345 | 630,071,124 | 634,859,673 | 633,474,090 | 629,408,397 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||
| Net sales (in thousands) | 1,329,700 | 1,310,200 | 1,376,000 | 1,216,600 | 1,191,700 | 1,140,900 | 925,000 | 1,128,700 | 1,174,100 | 1,094,000 | 1,086,900 | 993,000 | 977,700 | 906,600 | 943,700 | 894,800 | 888,500 | 821,500 | 841,800 | 883,500 | ||||||
| Sales per share2 | 8.40 | 8.16 | 7.90 | 7.20 | 7.02 | 7.01 | 6.95 | 7.24 | 6.93 | 6.64 | 6.35 | 6.11 | 5.97 | 5.79 | 5.65 | 5.45 | 5.45 | 0.00 | 0.00 | 0.00 | ||||||
| Share price1, 3 | 107.73 | 119.82 | 112.27 | 96.78 | 87.65 | 78.08 | 78.69 | 71.05 | 76.85 | 76.07 | 70.95 | 58.71 | 59.26 | 46.71 | 47.29 | 43.10 | 44.61 | 33.97 | 38.50 | 36.56 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||||
| P/S ratio4 | 12.83 | 14.68 | 14.21 | 13.45 | 12.48 | 11.14 | 11.32 | 9.82 | 11.09 | 11.46 | 11.17 | 9.61 | 9.92 | 8.06 | 8.37 | 7.91 | 8.18 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||||
| Abbott Laboratories | 4.78 | 5.38 | 5.36 | 5.64 | 6.30 | 6.13 | 5.77 | 5.09 | 4.83 | 4.72 | 4.98 | 4.52 | 4.37 | 3.98 | 3.84 | 3.57 | 3.84 | — | — | — | ||||||
| Bristol-Myers Squibb Co. | 3.16 | 2.85 | 3.44 | 3.28 | 3.16 | 3.66 | 3.97 | 4.45 | 5.52 | 3.87 | 3.11 | 3.21 | 3.67 | 3.64 | 4.38 | 4.04 | 5.02 | — | — | — | ||||||
| CVS Health Corp. | 0.47 | 0.45 | 0.39 | 0.40 | 0.35 | 0.32 | 0.32 | 0.30 | 0.37 | 0.38 | 0.33 | 0.36 | 0.39 | 0.42 | 0.37 | 0.36 | 0.38 | — | — | — | ||||||
| Danaher Corp. | 6.37 | 7.91 | 7.72 | 7.27 | 7.01 | 8.15 | 7.48 | 6.34 | 6.29 | 5.32 | 5.43 | 4.67 | 3.97 | 3.62 | 3.74 | 3.77 | 3.70 | — | — | — | ||||||
| Elevance Health Inc. | 0.81 | 0.78 | 0.73 | 0.76 | 0.60 | 0.61 | 0.63 | 0.65 | 0.74 | 0.67 | 0.77 | 0.69 | 0.88 | 0.79 | 0.72 | 0.68 | 0.67 | — | — | — | ||||||
| Intuitive Surgical Inc. | 17.89 | 22.12 | 21.73 | 23.19 | 21.29 | 20.09 | 18.44 | 13.33 | 15.01 | 15.41 | 15.28 | 15.83 | 16.06 | 16.36 | 17.01 | 16.16 | 14.97 | — | — | — | ||||||
| Medtronic PLC | 5.57 | 5.71 | 5.43 | 5.11 | 4.36 | 4.34 | 4.82 | 4.72 | 4.36 | 4.04 | 4.27 | 4.35 | 3.92 | 3.57 | 3.65 | 3.62 | 4.06 | — | — | — | ||||||
| UnitedHealth Group Inc. | 1.58 | 1.55 | 1.47 | 1.49 | 1.24 | 1.18 | 1.17 | 1.12 | 1.18 | 1.00 | 1.00 | 0.98 | 1.12 | 1.22 | 1.17 | 1.09 | 1.10 | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2021 Calculation
Sales per share
= (Net salesQ4 2021
+ Net salesQ3 2021
+ Net salesQ2 2021
+ Net salesQ1 2021)
÷ No. shares of common stock outstanding
= (1,329,700,000 + 1,310,200,000 + 1,376,000,000 + 1,216,600,000)
÷ 623,207,437 = 8.40
3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.
4 Q4 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 107.73 ÷ 8.40 = 12.83
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Edwards Lifesciences Corp. P/S ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021. |
Price to Book Value (P/BV)
Edwards Lifesciences Corp., historical P/BV calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 623,207,437 | 624,334,496 | 623,327,843 | 621,636,777 | 624,518,873 | 623,248,273 | 621,740,581 | 619,664,253 | 627,367,734 | 625,710,042 | 623,907,657 | 625,504,809 | 623,298,987 | 627,147,807 | 628,157,934 | 632,337,345 | 630,071,124 | 634,859,673 | 633,474,090 | 629,408,397 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||
| Stockholders’ equity (in thousands) | 5,835,900 | 5,541,300 | 5,133,300 | 4,658,400 | 4,574,300 | 4,210,300 | 3,839,100 | 3,901,100 | 4,148,300 | 3,814,800 | 3,500,300 | 3,447,500 | 3,140,400 | 3,361,300 | 3,164,200 | 3,245,700 | 2,956,200 | 3,162,500 | 2,939,600 | 2,742,700 | ||||||
| Book value per share (BVPS)2 | 9.36 | 8.88 | 8.24 | 7.49 | 7.32 | 6.76 | 6.17 | 6.30 | 6.61 | 6.10 | 5.61 | 5.51 | 5.04 | 5.36 | 5.04 | 5.13 | 4.69 | 4.98 | 4.64 | 4.36 | ||||||
| Share price1, 3 | 107.73 | 119.82 | 112.27 | 96.78 | 87.65 | 78.08 | 78.69 | 71.05 | 76.85 | 76.07 | 70.95 | 58.71 | 59.26 | 46.71 | 47.29 | 43.10 | 44.61 | 33.97 | 38.50 | 36.56 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||||
| P/BV ratio4 | 11.50 | 13.50 | 13.63 | 12.91 | 11.97 | 11.56 | 12.74 | 11.29 | 11.62 | 12.48 | 12.65 | 10.65 | 11.76 | 8.72 | 9.39 | 8.40 | 9.51 | 6.82 | 8.30 | 8.39 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||
| Abbott Laboratories | 5.75 | 6.61 | 6.38 | 6.27 | 6.65 | 6.30 | 5.94 | 5.40 | 4.96 | 4.65 | 4.86 | 4.49 | 4.38 | 3.94 | 3.72 | 3.23 | 3.40 | 2.95 | 2.71 | 2.42 | ||||||
| Bristol-Myers Squibb Co. | 4.07 | 3.48 | 4.15 | 3.73 | 3.55 | 2.87 | 2.82 | 2.77 | 2.80 | 5.30 | 4.63 | 4.91 | 5.89 | 5.89 | 7.67 | 6.65 | 8.88 | 6.75 | 6.05 | 6.36 | ||||||
| CVS Health Corp. | 1.83 | 1.71 | 1.47 | 1.51 | 1.33 | 1.24 | 1.24 | 1.21 | 1.47 | 1.47 | 1.23 | 1.25 | 1.29 | 2.17 | 1.95 | 1.73 | 1.88 | 1.94 | 2.34 | 2.38 | ||||||
| Danaher Corp. | 4.16 | 5.11 | 4.82 | 4.46 | 3.93 | 4.38 | 3.90 | 3.68 | 3.72 | 3.02 | 3.19 | 2.88 | 2.80 | 2.56 | 2.65 | 2.61 | 2.58 | 2.47 | 2.35 | 2.42 | ||||||
| Elevance Health Inc. | 3.07 | 2.88 | 2.67 | 2.78 | 2.19 | 2.10 | 2.06 | 2.23 | 2.42 | 2.13 | 2.40 | 2.15 | 2.82 | 2.45 | 2.24 | 2.26 | 2.24 | 2.04 | 1.84 | 1.82 | ||||||
| Intuitive Surgical Inc. | 8.59 | 10.64 | 10.35 | 10.40 | 9.53 | 9.35 | 9.19 | 7.22 | 8.13 | 8.43 | 8.49 | 8.68 | 8.96 | 9.30 | 10.03 | 9.71 | 9.91 | 8.35 | 7.62 | 7.21 | ||||||
| Medtronic PLC | 3.26 | 3.14 | 3.02 | 2.84 | 2.48 | 2.60 | 2.94 | 2.87 | 2.66 | 2.48 | 2.62 | 2.59 | 2.31 | 2.11 | 2.10 | 2.14 | 2.40 | 2.27 | 1.96 | 2.34 | ||||||
| UnitedHealth Group Inc. | 6.27 | 6.13 | 5.76 | 5.86 | 4.83 | 4.54 | 4.53 | 4.81 | 4.92 | 4.32 | 4.40 | 4.37 | 4.89 | 5.32 | 5.13 | 4.72 | 4.59 | 4.55 | 4.37 | 4.01 | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2021 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 5,835,900,000 ÷ 623,207,437 = 9.36
3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.
4 Q4 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 107.73 ÷ 9.36 = 11.50
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Edwards Lifesciences Corp. P/BV ratio decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |